Crossmark Global Holdings Inc. Trims Position in AstraZeneca PLC (NASDAQ:AZN)

Crossmark Global Holdings Inc. trimmed its position in AstraZeneca PLC (NASDAQ:AZN) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,121 shares of the company’s stock after selling 317 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in AstraZeneca were worth $3,481,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Stratos Wealth Advisors LLC grew its holdings in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares in the last quarter. Crumly & Associates Inc. grew its stake in AstraZeneca by 2.2% in the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after buying an additional 143 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in shares of AstraZeneca by 3.6% in the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after buying an additional 153 shares during the last quarter. Veery Capital LLC raised its position in shares of AstraZeneca by 4.7% during the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after buying an additional 157 shares in the last quarter. Finally, Harbour Investments Inc. lifted its holdings in shares of AstraZeneca by 1.9% during the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after acquiring an additional 160 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Up 0.4 %

Shares of AZN stock opened at $68.20 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50-day moving average of $66.20 and a 200 day moving average of $74.32. The stock has a market capitalization of $211.49 billion, a PE ratio of 32.63, a P/E/G ratio of 1.05 and a beta of 0.46. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the business earned $0.87 earnings per share. The business’s revenue was up 18.0% on a year-over-year basis. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.12 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of a number of research analyst reports. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, AstraZeneca has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.